Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.


Journal

Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872

Informations de publication

Date de publication:
05 2021
Historique:
received: 29 08 2020
accepted: 13 10 2020
revised: 12 10 2020
pubmed: 27 11 2020
medline: 28 1 2022
entrez: 26 11 2020
Statut: ppublish

Résumé

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Among human and mouse NK cells from the spleen and blood, we previously identified by single-cell RNA sequencing (scRNAseq) two similar major subsets, NK1 and NK2. Using the same technology, we report here the identification, by single-cell RNA sequencing (scRNAseq), of three NK cell subpopulations in human bone marrow. Pseudotime analysis identified a subset of resident CD56

Identifiants

pubmed: 33239726
doi: 10.1038/s41423-020-00574-8
pii: 10.1038/s41423-020-00574-8
pmc: PMC8093261
doi:

Substances chimiques

Antigens, CD 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1290-1304

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Références

Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44–49 (2011).
pubmed: 21212348 pmcid: 3089969 doi: 10.1126/science.1198687
Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev. Immunol. 19, 197–223 (2001).
pubmed: 11244035 doi: 10.1146/annurev.immunol.19.1.197
Narni-Mancinelli, E., Ugolini, S. & Vivier, E. Tuning the threshold of natural killer cell responses. Curr. Opin. Immunol. 25, 53–58 (2013).
pubmed: 23270590 doi: 10.1016/j.coi.2012.11.005
Guia, S., Fenis, A., Vivier, E. & Narni-Mancinelli, E. Activating and inhibitory receptors expressed on innate lymphoid cells. Semin Immunopathol. 40, 331–341 (2018).
pubmed: 29789862 doi: 10.1007/s00281-018-0685-x
Spits, H. et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013).
pubmed: 23348417 doi: 10.1038/nri3365
Walzer, T., Jaeger, S., Chaix, J. & Vivier, E. Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr. Opin. Immunol. 19, 365–372 (2007b).
pubmed: 17442558 doi: 10.1016/j.coi.2007.04.004
Yu, J. et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J. Clin. Invest 121, 1456–1470 (2011).
pubmed: 21364281 pmcid: 3069763 doi: 10.1172/JCI43242
Bjorkstrom, N. K., Ljunggren, H. G. & Michaelsson, J. Emerging insights into natural killer cells in human peripheral tissues. Nat. Rev. Immunol. 16, 310–320 (2016).
pubmed: 27121652 doi: 10.1038/nri.2016.34
Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633–640 (2001).
pubmed: 11698225 doi: 10.1016/S1471-4906(01)02060-9
Hanna, J. et al. Novel insights on human NK cells’ immunological modalities revealed by gene expression profiling. J. Immunol. 173, 6547–6563 (2004).
pubmed: 15557145 doi: 10.4049/jimmunol.173.11.6547
Yu, J., Freud, A. G. & Caligiuri, M. A. Location and cellular stages of natural killer cell development. Trends Immunol. 34, 573–582 (2013).
pubmed: 24055329 doi: 10.1016/j.it.2013.07.005
Crinier, A. et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity 49, 971–986 e975 (2018).
pubmed: 30413361 pmcid: 6269138 doi: 10.1016/j.immuni.2018.09.009
Dulphy, N. et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J. Immunol. 181, 2227–2237 (2008).
pubmed: 18641363 doi: 10.4049/jimmunol.181.3.2227
Chan, A. et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J. Immunol. 179, 89–94 (2007).
pubmed: 17579025 doi: 10.4049/jimmunol.179.1.89
Lopez-Verges, S. et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725–14732 (2011).
pubmed: 21825173 pmcid: 3169160 doi: 10.1073/pnas.1110900108
Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106, 1915–1919 (2009).
pubmed: 19181844 pmcid: 2644138 doi: 10.1073/pnas.0813192106
Bjorkstrom, N. K. et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208, 13–21 (2011).
pubmed: 21173105 pmcid: 3023129 doi: 10.1084/jem.20100762
Abdul-Careem, M. F. et al. Critical role of natural killer cells in lung immunopathology during influenza infection in mice. J. Infect. Dis. 206, 167–177 (2012).
pubmed: 22561366 doi: 10.1093/infdis/jis340
Dou, Y. et al. Influenza vaccine induces intracellular immune memory of human NK cells. PLoS One 10, e0121258 (2015).
pubmed: 25781472 pmcid: 4363902 doi: 10.1371/journal.pone.0121258
Cichocki, F. et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia 30, 456–463 (2016).
pubmed: 26416461 doi: 10.1038/leu.2015.260
Lee, J. et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442 (2015).
pubmed: 25786175 pmcid: 4537797 doi: 10.1016/j.immuni.2015.02.013
Tesi, B., Schlums, H., Cichocki, F. & Bryceson, Y. T. Epigenetic regulation of adaptive NK cell diversification. Trends Immunol. 37, 451–461 (2016).
pubmed: 27160662 doi: 10.1016/j.it.2016.04.006
Short, N. J. et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 10, 506–525 (2020).
pubmed: 32014868 doi: 10.1158/2159-8290.CD-19-1011
Costello, R. T. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99, 3661–3667 (2002).
pubmed: 11986221 doi: 10.1182/blood.V99.10.3661
Fauriat, C. et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109, 323–330 (2007).
pubmed: 16940427 doi: 10.1182/blood-2005-08-027979
Chretien, A. S. et al. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology 6, e1307491 (2017a).
pubmed: 29209559 pmcid: 5706596 doi: 10.1080/2162402X.2017.1307491
Chretien, A. S. et al. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget 8, 49548–49563 (2017c).
pubmed: 28548938 pmcid: 5564787 doi: 10.18632/oncotarget.17747
Chretien, A. S. et al. Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia. Front Immunol. 8, 573 (2017b).
pubmed: 28611767 pmcid: 5447002 doi: 10.3389/fimmu.2017.00573
Pende, D. et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105, 2066–2073 (2005).
pubmed: 15536144 doi: 10.1182/blood-2004-09-3548
Sanchez-Correa, B. et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol. Cell Biol. 90, 109–115 (2012).
pubmed: 21383766 doi: 10.1038/icb.2011.15
Stringaris, K. et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99, 836–847 (2014).
pubmed: 24488563 pmcid: 4008119 doi: 10.3324/haematol.2013.087536
Chiossone, L., Dumas, P. Y., Vienne, M. & Vivier, E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18, 671–688 (2018).
pubmed: 30209347 doi: 10.1038/s41577-018-0061-z
Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601 pmcid: 5241818 doi: 10.1038/ncomms14049
Bjorklund, A. K. et al. The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing. Nat. Immunol. 17, 451–460 (2016).
pubmed: 26878113 doi: 10.1038/ni.3368
Huntington, N. D. et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med 206, 25–34 (2009).
pubmed: 19103877 pmcid: 2626663 doi: 10.1084/jem.20082013
van Helden, M. J. et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J. Exp. Med 212, 2015–2025 (2015).
pubmed: 26503444 pmcid: 4647267 doi: 10.1084/jem.20150809
Costa-Garcia, M. et al. Human cytomegalovirus antigen presentation by HLA-DR+ NKG2C+ adaptive NK cells specifically activates polyfunctional effector memory CD4+ T lymphocytes. Front Immunol. 10, 687 (2019).
pubmed: 31001281 pmcid: 6456717 doi: 10.3389/fimmu.2019.00687
Liu, L. L. et al. Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. Cell Rep. 15, 1088–1099 (2016).
pubmed: 27117418 pmcid: 4858565 doi: 10.1016/j.celrep.2016.04.005
Liu, L. L. et al. Harnessing adaptive natural killer cells in cancer immunotherapy. Mol. Oncol. 9, 1904–1917 (2015).
pubmed: 26604011 pmcid: 5528731 doi: 10.1016/j.molonc.2015.10.001
Schlums, H. et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42, 443–456 (2015).
pubmed: 25786176 pmcid: 4612277 doi: 10.1016/j.immuni.2015.02.008
Cichocki, F. et al. ARID5B regulates metabolic programming in human adaptive NK cells. J. Exp. Med. 215, 2379–2395 (2018).
pubmed: 30061358 pmcid: 6122973 doi: 10.1084/jem.20172168
Beziat, V. et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121, 2678–2688 (2013).
pubmed: 23325834 pmcid: 3617633 doi: 10.1182/blood-2012-10-459545
Stumpo, D. J. et al. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 114, 2401–2410 (2009).
pubmed: 19633199 pmcid: 2746470 doi: 10.1182/blood-2009-04-214619
Zhang, L. et al. ZFP36L2 is required for self-renewal of early burst-forming unit erythroid progenitors. Nature 499, 92–96 (2013).
pubmed: 23748442 pmcid: 3702661 doi: 10.1038/nature12215
Walzer, T. et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8, 1337–1344 (2007a).
pubmed: 17965716 doi: 10.1038/ni1523
Chea, S. et al. CXCR6 expression is important for retention and circulation of ILC precursors. Mediators Inflamm. 2015, 368427 (2015).
pubmed: 26494947 pmcid: 4606447 doi: 10.1155/2015/368427
Burgess, M. et al. CD62L as a therapeutic target in chronic lymphocytic leukemia. Clin. Cancer Res. 19, 5675–5685 (2013).
pubmed: 23948971 doi: 10.1158/1078-0432.CCR-13-1037
Avigdor, A. et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103, 2981–2989 (2004).
pubmed: 15070674 doi: 10.1182/blood-2003-10-3611
Beziat, V., Descours, B., Parizot, C., Debre, P. & Vieillard, V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 5, e11966 (2010).
pubmed: 20700504 pmcid: 2917352 doi: 10.1371/journal.pone.0011966
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
pubmed: 24658644 pmcid: 4122333 doi: 10.1038/nbt.2859
Renoux, V. M. et al. Identification of a human natural killer cell lineage-restricted progenitor in fetal and adult tissues. Immunity 43, 394–407 (2015).
pubmed: 26287684 doi: 10.1016/j.immuni.2015.07.011
Leavy, O. Natural killer cells: RAG keeps natural killers fit. Nat. Rev. Immunol. 14, 716–717 (2014).
pubmed: 25301254 doi: 10.1038/nri3760
Rabacal, W. et al. Transcription factor KLF2 regulates homeostatic NK cell proliferation and survival. Proc. Natl Acad. Sci. USA 113, 5370–5375 (2016).
pubmed: 27114551 pmcid: 4868471 doi: 10.1073/pnas.1521491113
Celis-Gutierrez, J. et al. Dok1 and Dok2 proteins regulate natural killer cell development and function. EMBO J. 33, 1928–1940 (2014).
pubmed: 24963146 pmcid: 4195787 doi: 10.15252/embj.201387404
Huang, L., Zhu, P., Xia, P. & Fan, Z. WASH has a critical role in NK cell cytotoxicity through Lck-mediated phosphorylation. Cell Death Dis. 7, e2301 (2016).
pubmed: 27441653 pmcid: 4973352 doi: 10.1038/cddis.2016.212
Jevremovic, D. et al. Cutting edge: a role for the adaptor protein LAT in human NK cell-mediated cytotoxicity. J. Immunol. 162, 2453–2456 (1999).
pubmed: 10072481
Awasthi, A. et al. Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes. J. Exp. Med 207, 1923–1938 (2010).
pubmed: 20733035 pmcid: 2931159 doi: 10.1084/jem.20100040
Mace, E. M. & Orange, J. S. Lytic immune synapse function requires filamentous actin deconstruction by Coronin 1A. Proc. Natl Acad. Sci. USA 111, 6708–6713 (2014).
pubmed: 24760828 pmcid: 4020046 doi: 10.1073/pnas.1314975111
Sasanuma, H. et al. Dual function for the adaptor MIST in IFN-gamma production by NK and CD4+NKT cells regulated by the Src kinase Fgr. Blood 107, 3647–3655 (2006).
pubmed: 16439675 doi: 10.1182/blood-2005-10-4102
Wilton, K. M., Overlee, B. L. & Billadeau, D. D. NKG2D-DAP10 signaling recruits EVL to the cytotoxic synapse to generate F-actin and promote NK cell cytotoxicity. J. Cell Sci. 133, 1–12 (2019).
Witalisz-Siepracka, A. et al. Loss of JAK1 drives innate immune deficiency. Front. Immunol. 9, 3108 (2018).
pubmed: 30671064 doi: 10.3389/fimmu.2018.03108
Crozat, K. et al. Impact of beta2 integrin deficiency on mouse natural killer cell development and function. Blood 117, 2874–2882 (2011).
pubmed: 21239699 doi: 10.1182/blood-2010-10-315457
Viant, C. et al. SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat. Commun. 5, 5108 (2014).
pubmed: 25355530 doi: 10.1038/ncomms6108
Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).
pubmed: 31477722 pmcid: 6718415 doi: 10.1038/s41467-019-11947-7
Lim, A. I. et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell 168, 1086–1100 e1010 (2017).
pubmed: 28283063 doi: 10.1016/j.cell.2017.02.021
Romagnani, C. et al. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J. Immunol. 178, 4947–4955 (2007).
pubmed: 17404276 doi: 10.4049/jimmunol.178.8.4947
Freud, A. G., Yu, J. & Caligiuri, M. A. Human natural killer cell development in secondary lymphoid tissues. Semin Immunol. 26, 132–137 (2014).
pubmed: 24661538 pmcid: 4010312 doi: 10.1016/j.smim.2014.02.008
Lugthart, G. et al. Human lymphoid tissues harbor a distinct CD69+CXCR6+ NK cell population. J. Immunol. 197, 78–84 (2016).
pubmed: 27226093 doi: 10.4049/jimmunol.1502603
Melsen, J. E., Lugthart, G., Lankester, A. C. & Schilham, M. W. Human circulating and tissue-resident CD56(bright) natural killer cell populations. Front Immunol. 7, 262 (2016).
pubmed: 27446091 pmcid: 4927633 doi: 10.3389/fimmu.2016.00262
Bruck, O. et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv. 4, 274–286 (2020).
pubmed: 31968078 pmcid: 6988390 doi: 10.1182/bloodadvances.2019000792
Khaznadar, Z. et al. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur. J. Immunol. 44, 3068–3080 (2014).
pubmed: 25041786 doi: 10.1002/eji.201444500
Scoville, S. D. et al. Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132, 1792–1804 (2018).
pubmed: 30158248 pmcid: 6202909 doi: 10.1182/blood-2018-03-838474
Le Bouteiller, P. et al. CD160: A unique activating NK cell receptor. Immunol. Lett. 138, 93–96 (2011). 
pubmed: 21324341 doi: 10.1016/j.imlet.2011.02.003
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495–502 (2015).
pubmed: 25867923 pmcid: 4430369 doi: 10.1038/nbt.3192
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
pubmed: 30643263 pmcid: 6340744 doi: 10.1038/s41590-018-0276-y
Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 4, 1184–1191 (2009).
pubmed: 19617889 pmcid: 3159387 doi: 10.1038/nprot.2009.97
Falcon, S. & Gentleman, R. Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257–258 (2007).
pubmed: 17098774 doi: 10.1093/bioinformatics/btl567
Goldman, M. J. et al. A user guide for the online exploration and visualization of PCAWG data. Nat. Commun. 11, 3400–3409 (2020). 
pubmed: 32636365 pmcid: 7340791 doi: 10.1038/s41467-020-16785-6

Auteurs

Adeline Crinier (A)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Pierre-Yves Dumas (PY)

CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.
Bordeaux University, Bordeaux, France.
Institut National de la Santé et de la Recherche Médicale, U1035, Bordeaux, France.

Bertrand Escalière (B)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Christelle Piperoglou (C)

APHM, Hôpital de la Timone, Marseille-Immunopôle, Marseille, France.

Laurine Gil (L)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Arnaud Villacreces (A)

Bordeaux University, Bordeaux, France.
Institut National de la Santé et de la Recherche Médicale, U1035, Bordeaux, France.

Frédéric Vély (F)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
APHM, Hôpital de la Timone, Marseille-Immunopôle, Marseille, France.

Zoran Ivanovic (Z)

Institut National de la Santé et de la Recherche Médicale, U1035, Bordeaux, France.
Établissement Français du Sang Nouvelle Aquitaine, Bordeaux, France.

Pierre Milpied (P)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Émilie Narni-Mancinelli (É)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France. narni@ciml.univ-mrs.fr.

Éric Vivier (É)

Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France. vivier@ciml.univ-mrs.fr.
APHM, Hôpital de la Timone, Marseille-Immunopôle, Marseille, France. vivier@ciml.univ-mrs.fr.
Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. vivier@ciml.univ-mrs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH